Wondertox 200U Neurotoxin Protocol

Botulinum Toxin Type A (200U) | Clostridium Botulinum CBFC26 Strain

Lyophilized formulation yielding 99.5% active neurotoxin purity. Validated via Phase III trials for neuromuscular intervention and facial rhytid management.

Purity & Composition

Active Neurotoxin: 99.5%

Residual Protein: 0.02% (HPLC verified)

Stabilizer: 0.5mg Human Serum Albumin (HSA)

Buffer: 0.9% Sodium Chloride

Manufacturing QA

Standard: & facility

Sterilization: 0.22μm Terminal Filtration

Endotoxin Limit: USP <85 compliance

Stability: 36-month baseline at 2-8°C

Clinical Performance Data (Phase III)

Administration Protocol

01. Dilution

0.9% sterile preservative-free saline required.

02. Reconstitution

Allow 30-60 minutes settling time. Do not agitate.

03. Application

Administer utilizing 31G standardized.

04. Storage

Refrigerate 2-8°C post-dilution. Discard after 24h.

Medical Disclaimer & Efficacy Notice

Restriction: Distribution and administration strictly limited to board-certified medical personnel.

Contraindication: Unsafe for neuromuscular disorder profiles (prevalence rate: 4.7% in cohort tracking).

Variance: Target muscle response yields a documented ±15% potency fluctuation based on individual neuromuscular physiology.